# A Validation and Dosimetry Study of GSK2634673F PET Ligand

> **NCT02052297** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 19 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **OTHER:** GSK2634673F

## Key facts

- **NCT ID:** NCT02052297
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01-24
- **Primary completion:** 2016-04-21
- **Final completion:** 2016-04-21
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** The study was terminated due to challenges recruiting subjects with fibrotic interstitial lung disease associated with a connective tissue disease for Part D
- **Last updated:** 2018-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02052297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02052297, "A Validation and Dosimetry Study of GSK2634673F PET Ligand". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02052297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*